Neonatal Mask Seal; a Two-handed Versus One-handed Approach: The NeoSeal Study (NeoSeal)

May 7, 2026 updated by: University College Dublin

Neonatal Mask Seal; a Randomised Controlled Trial of Two-handed Versus One-handed Hold for Delivering Positive-pressure Ventilation With a Facemask in Preterm and Term Infants: The NeoSeal Study

When babies can't breathe effectively, we can use a facemask to give them breaths and oxygen. The mask can be held with one or two hands, depending on the preference of the doctor. Both types of mask holds are recommended in international guidelines, but it is unclear which one is better for the baby. If a lot of air is leaking around the mask, it means that the baby is not getting the full breathing support that the healthcare providers are trying to give. There currently is not enough evidence to say which type of hold is better to reduce this potential leaking of air.

In this study, the investigators will compare two different ways of holding a mask on a baby's face to help them breathe. Each baby will be randomly allocated to either a one-handed or a two-handed mask hold, and the investigators will measure how much air leaks out around the mask during each breath. Any baby in the neonatal unit may be included in this study.

Study Overview

Detailed Description

This study will compare the measured leak in mask ventilation delivered by a healthcare professional in the neonatal team, using a one-handed versus a two-handed hold with a standardised mask size and shape. This is to assess the two-handed technique as a potential first-line approach in neonatal bag-mask ventilation.

The handholds will be assessed by a randomised controlled trial, with the two-handed hold as the intervention and the one-handed hold as the control.

The population that will be studied is neonates in the neonatal intensive care unit (NICU), at any gestation, who the clinical team have decided to intubate.

A member of the research team, who will provide an out-of-hours on call service, will attend the event. The relevant outcomes will be measured by the Monivent Neo100, which will be set up by the research team. Standardised masks, as used per local protocol, will be used, with the sensor module placed between that and the T-piece with an adaptor.

The outcomes will assess the effectiveness of both the intervention and control, including ventilation parameters recorded by the Monivent Neo100 and the clinical stability of the patient. The primary outcome of this study is the percentage mask leak.

A research team member will record data for primary and secondary outcome. The event will be filmed for post-hoc video analysis.

The outcome assessor will be blinded to the group allocation.

This research project will take place over 24 months, with an interim analysis to ensure recruitment is projected to achieve sample size.

Study Type

Interventional

Enrollment (Actual)

110

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Leinster
      • Dublin, Leinster, Ireland, D02 YH21
        • The National Maternity Hospital Dublin

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • All term and preterm neonates in the neonatal unit who the clinical team have decided to intubate, with or without pre-medication and who require mask ventilation prior to intubation attempt.

Exclusion Criteria:

  • Neonates with a congenital malformation that would impact mask seal will not be included.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intervention: Two-handed facemask hold
Two-handed mask hold technique while giving facemask ventilation, with another operator designated to deliver positive inspiratory pressure (PIP) via the T-piece. The operators may be any member of the neonatal team, who have undergone Neonatal Resusctiation Programme (NRP) certification. Standardised mask size and shape for gestation and weight, as per local policy, will be used.
Two-handed mask hold technique while giving facemask ventilation, with another operator designated to deliver PIP via the T-piece.
Placebo Comparator: Control: One-handed facemask hold
One-handed mask hold technique while giving facemask ventilation, with the same operator holding the mask and delivering positive pressure ventilation (PPV) via the T-piece.
One-handed mask hold technique while giving facemask ventilation, with the same operator holding the mask and delivering PPV via the T-piece.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mask leak
Time Frame: Over a maximum of 20 minutes

Mask leak percentage, as measured by the Monivent Respiratory Function Monitor (RFM).

Collected over a minimum of 5 breaths. Maximum of 2 episodes of facemask ventilation will be collected, with values averaged.

Over a maximum of 20 minutes

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Lowest oxygen saturation
Time Frame: Over a maximum of 20 minutes
Lowest oxygen saturation detected on the bedside clinical monitoring (Philips Intellivue MX800) during the period of facemask ventilation, recorded by a member of the research team.
Over a maximum of 20 minutes
Highest supplemental FiO2 used during facemask ventilation
Time Frame: Over a maximum of 20 minutes
Highest percentage FiO2 used during the period of facemask ventilation, as indicated by the set dial on the Neopuff.
Over a maximum of 20 minutes
Positive inspiratory pressure during facemask ventilation
Time Frame: Over a maximum of 20 minutes
Positive inspiratory pressure used during the period of facemask ventilation, as measured by the Monivent Neo100 respiratory function monitor.
Over a maximum of 20 minutes
Percentage of obstructed breaths during facemask ventilation
Time Frame: Over a maximum of 20 minutes
Percentage of obstructed breaths during the period of facemask ventilation, as measured by the Monivent Neo100 respiratory function monitor.
Over a maximum of 20 minutes
Tidal volume during facemask ventilation
Time Frame: Over a maximum of 20 minutes
Measured tidal volume during the period of facemask ventilation, as measured by the Monivent Neo100 respiratory function monitor.
Over a maximum of 20 minutes
Number of times facemask position is adjusted during facemask ventilation
Time Frame: Over a maximum of 20 minutes
Number of times clinical team needs to adjust mask position during the period of facemask ventilation.
Over a maximum of 20 minutes
Duration of facemask ventilation
Time Frame: Over a maximum of 20 minutes
Time duration of facemask ventilation
Over a maximum of 20 minutes
Crossover to other handhold
Time Frame: Over a maximum of 20 minutes

If allocated two-handed hold: Number of times clinical team elect to switch to one-handed hold.

If allocated one-handed hold: Number of times clinical team elect to switch to two-handed hold.

Over a maximum of 20 minutes
User opinion of mask hold
Time Frame: Over a maximum of 20 minutes
Survey of operator opinions about mask hold used, and their usual preference.
Over a maximum of 20 minutes
Lowest heart rate
Time Frame: Over a maximum of 20 minutes
Lowest heart rate detected on the bedside clinical monitoring (Philips Intellivue MX800) during the period of facemask ventilation, recorded by a member of the research team.
Over a maximum of 20 minutes

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 27, 2025

Primary Completion (Actual)

April 21, 2026

Study Completion (Actual)

April 21, 2026

Study Registration Dates

First Submitted

November 21, 2024

First Submitted That Met QC Criteria

December 13, 2024

First Posted (Actual)

December 18, 2024

Study Record Updates

Last Update Posted (Actual)

May 12, 2026

Last Update Submitted That Met QC Criteria

May 7, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Data will be pseudononymised and will be presented/shared only as collated values, as opposed to individual results.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Neonatal Intensive Care

Clinical Trials on Two-handed facemask hold

Subscribe